Company News
【Conference Announcement】Frontera Therapeutics to Present Innovative Achievements at ARVO 2026
As an internationally leading enterprise focused on the R&D and manufacturing of rAAV gene therapy, Frontera Therapeutics has continued to deepen its efforts in the gene therapy field and achieved continuous breakthroughs. In May 2026, Frontera Therapeutics will present multiple latest clinical research achievements at the 2026 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO), a globally authoritative academic event.
Dates: May 3–7, 2026
Venue: Denver, USA
About ARVO
Founded in 1928, ARVO is the world’s largest and most prominent professional event for ophthalmology and vision research. The theme of the 2026 Annual Meeting is “Achieving Precision Ophthalmology through Innovative Vision Research”. Over 11,000 basic science and clinical researchers from more than 70 countries are expected to attend.
Frontera Therapeutics has been invited to deliver oral presentations at ARVO 2026 on Phase II clinical trial results for both “neovascular age-related macular degeneration (nAMD)” and “X-linked retinitis pigmentosa (XLRP)”.
Frontera Therapeutics sincerely invites attendees to engage with its presentations and join discussions on the current status and prospects of gene therapy drug development for chronic and inherited ophthalmic diseases.
Details of Frontera Therapeutics‘s presentations are as follows:
Presentation Type | Oral Session | |
Title | Phase II Preliminary Results of Subretinal Gene Therapy FT - 002 in Pediatric Participants with RPGR - associated XLRP | 28 - Week Interim Results of Phase II Study Evaluating Intravitreal Gene Therapy FT - 003 in naïve and Pre - treated Participants with nAMD |
No of Conference | 543 | 543 |
Heading | First - in - human and preclinical gene therapies | First - in - human and preclinical gene therapies |
Date | 7-May-26 | 7-May-26 |
Duration | 2:00 PM to 2:15 PM | 3:15 PM to 3:30 PM |
Conference Room | Bluebird Ballroom 1B | Bluebird Ballroom 1B |
Preview and Outlook
Dr. Xinyan Li, Chief Executive Officer of Frontera Therapeutics, stated :“Currently, multiple gene therapy drugs developed by Frontera Therapeutics are successively entering pivotal clinical stages. The clinical results obtained so far have demonstrated strong competitiveness, and several candidates have the potential to be global best-in-class therapies. By participating in this conference, Frontera Therapeutics will not only showcase the latest clinical research achievements in gene therapy, but also share experience and exchange knowledge with global peers to further advance gene therapy technologies and provide more treatment opportunities for patients worldwide.”
沪公网安备31011502401398号